Lil­ly to pay up to $415M in ALS deal; Ac­tu­ate’s mid-stage pan­cre­at­ic can­cer da­ta

Plus, news about Atara Bio­ther­a­peu­tics, Im­mutep, blue­bird bio, OSE Im­munother­a­peu­tics, Mer­sana Ther­a­peu­tics, In­novent, Bio­mea Fu­sion and Trail­head Biosys­tems:

Eli Lil­ly does an­oth­er ALS deal: The …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER